Turbine Simulated Cell Technologies raises £22.8m Series B for AI drug discovery platform

Turbine Simulated Cell Technologies Ltd develops an AI-driven Simulated Cell platform that creates digital twins of human cells to conduct virtual experiments for drug discovery and development. Based in London, the company provides computational modeling services to biopharmaceutical and pharmaceutical R&D organizations to identify therapeutic targets and predict drug responses, primarily in the field of oncology.

The company has raised £22.8m in a Series B funding round. This investment brings the post-money valuation of the business to £70.3m. The allotment of shares for this round took place in December 2025, with formal documentation filed in March.

Founded in 2019, Turbine Simulated Cell Technologies Ltd addresses the complexities of drug response prediction by simulating how cancer cells behave under various conditions. This digital approach allows researchers to test hypotheses in a virtual environment before proceeding to physical laboratory trials. The platform is designed to reduce the failure rate of drug candidates by providing deeper insights into cellular biology during the early stages of research.

In conjunction with the funding, Laszlo Robert Czirjak was appointed to the board of directors in December 2025.

The company focuses on providing its technology to the oncology sector, where understanding cellular mechanisms is critical for developing effective treatments. This latest capital injection follows the company's growth since its incorporation and supports its ongoing development of computational models for the pharmaceutical industry.